Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease

COMPASS trial found rivaroxaban plus aspirin improved CV endpoints vs aspirin alone. This analysis found that in those that discontinued rivaroxaban & aspirin to non-study aspirin had a similar rate of CV death, and a higher risk of stroke vs those allocated aspirin alone.

Source:

Heart